(Reuters) - Mylan NV said Teva Pharmaceutical Industries Ltd , which has made an unsolicited offer for the company, violated U.S. anti-trust rules by acquiring a stake.
Teva disclosed a 1.35 percent stake in MYLAN (MYL.NQ)(MYL.NQ)last week.
"We consider Teva's stakebuilding as a further indication of its intention to meddle with our business, strategy and mission while remaining unclear as to its actual intentions," Mylan said in a letter addressed to Teva's chief executive, Erez Vigodman.(http://1.usa.gov/1Q0SxgC)
Mylan did not clarify which anti-trust rule Teva violated.
The two companies were not immediately available for comment.
Mylan said on Monday there was still no clarity whether Teva would make a formal offer, almost six weeks since Teva's offer for about $40 billion.
(Reporting by Anjali Rao Koppala in Bengaluru; Editing by Maju Samuel)
Relacionados
- Fitch podría bajar el rating de OHL por escándalo en México
- El 79% de los inversores podría perder el interés por empresas víctimas de ciberataques
- Economía/Empresas.- El 79% de los inversores podría perder el interés por empresas víctimas de ciberataques
- Chiellini 'reta' a Messi para la final de Champions: "El gol al Athletic no podría marcarlo en Italia"
- La próxima consola de Nintendo podría estar basada en Android
